POAI Reports Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Financial Performance: Predictive Oncology reported a dramatic 96% decline in GAAP revenue to $2,682 for Q2 2025, with operating losses narrowing to $(1,978,895) due to cost containment rather than sales recovery. The company continues to rely on external financing as cash reserves decreased to $506,078.
Strategic Focus and Future Plans: The company is transitioning towards AI-driven drug discovery and expanding its ChemoFx assay, with plans for U.S. and European launches in late 2025. However, no financial guidance was provided, and the management highlighted the need for additional funding to sustain operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
